Document is current

Article History

Accepted: 4 March 2024

First Online: 2 April 2024

Declarations

:

: This study was funded by Genor Biopharma Co., Ltd., (Shanghai, China), the Major Project of National Science and Technology “Creation of Major New Drugs” (no. 2020ZX09201026), from the Ministry of Science and Technology of China, and Guangzhou Health Science and Technology Project (2021A031005).

: The data that support the findings of this study are available from the corresponding author, (Yi Fang, phaseistudy@163.com), upon reasonable request.

: Not applicable.

: Tong Li is an employee of Genor Biopharma Co., Ltd., (Shanghai, China). Lun Ou is an employee of Beijing United-Power Pharma Tech Co., Ltd., (Beijing, China). The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

: All studies were approved by the Ethics Committee of the Fifth Affiliated Hospital of Guangzhou Medical University (number: GYWY-Y2021-24, date: 2021/03/02) and were conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines.

: Informed consent was obtained from all individual participants included in the study.

: All authors contributed to the study’s conception and design. Material preparation, data collection, and analysis were performed by Yu Zhu, Chen Li, Haiyan Liu, Xuan Wang, Tenghua Wang, Jingyuan Tian, Xintong Liang, and Zhiqin Hu. The first draft of the manuscript was written by Yu Zhu and Chen Li. All authors commented on previous versions of the manuscript and approved the final manuscript.

: Not applicable.